Comparison of two preoperative glycemic optimization strategies before penile prosthesis implantation: a pilot randomized controlled trial
Objective To explore, in a pilot randomized controlled trial, whether two different preoperative glycemic optimization strategies — a two-week strategy targeting random blood glucose ≤ 200 mg/dL versus a three-month strategy targeting HbA1c < 8.5% — are associated with different surgical site infection (SSI) rates in diabetic men undergoing malleable penile prosthesis implantation (PPI), and to generate effect-size estimates to inform a definitive trial. Because the strategies differ in glycemic metric and target as well as duration, any observed difference cannot be attributed to duration of optimization alone. Patients and methods Forty-two diabetic men with erectile dysfunction and glycated hemoglobin (HbA1c) > 8.5% scheduled for malleable PPI at a single tertiary academic center were randomized 1:1 to Group A (short-term, two-week optimization targeting random blood glucose ≤ 200 mg/dL) or Group B (three-month optimization targeting HbA1c < 8.5%). The primary outcome was SSI within three months. Diabetes was co-managed by the endocrinology service. Given the small size, the study was pre-specified as a pilot; no non-inferiority margin was defined. Results All 42 patients completed follow-up. Baseline HbA1c at enrolment was similar between groups (both > 8.5%; Table 1), but preoperative HbA1c immediately before surgery was significantly higher in Group A than Group B (9.20 ± 0.78% vs. 7.62 ± 0.47%, p < 0.001), reflecting their assigned optimization strategies. Superficial SSI occurred in 3/21 (14.3%) in Group A versus 1/21 (4.8%) in Group B (risk difference 9.5%; OR 2.59; p = 0.606). Post-hoc power for this comparison was ~ 19%. No deep infections requiring prosthesis removal occurred. In an exploratory, descriptive comparison (4 infected vs. 38 non-infected patients), infected patients had a numerically higher mean preoperative HbA1c (9.40 ± 1.76% vs. 8.31 ± 0.88%; p = 0.30, Welch’s t-test) and BMI (27.8 ± 2.5 vs. 24.9 ± 1.6 kg/m²; p = 0.10, Welch’s t-test). Conclusion This pilot was underpowered and observed a non-significant three-fold higher SSI rate with the two-week, glucose-targeted strategy compared with the three-month, HbA1c-targeted strategy. Because the two strategies differ in duration, glycemic metric, and achieved control, this difference cannot be attributed to duration of optimization alone. The data neither establish nor exclude a clinically important difference and must be regarded as hypothesis-generating only; they should not be interpreted as evidence that either strategy is safe or non-inferior to the other. A definitive multicenter trial is warranted, using a prespecified non-inferiority margin, intra/postoperative glucose monitoring, and blinded outcome assessment; our data suggest a preliminary planning estimate of approximately 300 patients, which is unstable because it is derived from only four events. Findings apply specifically to malleable devices.
Authors
- Galal Elshorbagy (ORCID: https://orcid.org/0000-0002-7511-792X)
- Amr Elkady
- Mohamed Abdullahi (ORCID: https://orcid.org/0009-0001-8096-5536)
- Ragab Bakr
Institutions
- Cairo University (EG)
Publication Details
- Journal
- African Journal of Urology
- Published
- 2026-11-20
- DOI
- https://doi.org/10.1186/s12301-026-00638-7
- Primary Topic
- Hyperglycemia and glycemic control in critically ill and hospitalized patients
- Type
- article
- Field-Weighted Citation Impact
- 0.00